Neurology & CNS · Phase III

Top sponsors

• HOFFMANN-LA ROCHE 21 programs
• Teva Pharma 12 programs
• Novartis India 10 programs
• Takeda 10 programs
• Bristol-Myers Squibb Australia 9 programs
• Jazz Pharmaceuticals Ireland 7 programs
• Biogen 6 programs
• TG THERAPEUTICS 6 programs
• Acadia Pharmaceuticals 5 programs
• Anaxis Pharma 5 programs
• NEUROCRINE BIOSCIENCES 5 programs
• SUPERNUS PHARMACEUTICALS 5 programs

1. Pimavanserin

   Acadia Pharmaceuticals B.V.

   Schizophrenia

   phase 3 · small molecule · completed

   4 trials →

2. Pimavanserin

   Acadia Pharmaceuticals B.V.

   Neuropsychiatric Symptoms Related to Neurodegenerative Disease

   phase 3 · small molecule · completed

   2 trials →

3. Pimavanserin tartrate (ACP-103)

   Acadia Pharmaceuticals B.V.

   Parkinson's Disease Psychosis

   phase 3 · small molecule · completed

   4 trials →

4. Pioglitazone

   Takeda

   Mild Cognitive Impairment Due to Alzheimer's Disease

   phase 3 · small molecule · terminated

   2 trials →

5. Placebo

   Hoffmann-La Roche

   Schizophrenia

   phase 3 · small molecule · completed

   1 trial →

6. Placebo

   Jazz Pharmaceuticals Ireland Limited

   Multiple Sclerosis

   phase 3 · small molecule · completed

   1 trial →

7. Placebo

   SUPERNUS PHARMACEUTICALS, INC.

   Epilepsies, Partial

   phase 3 · small molecule · completed

   1 trial →

8. Placebo

   NEUROCRINE BIOSCIENCES INC

   Schizophrenia

   phase 3 · small molecule · completed

   2 trials →

9. Placebo

   Sumitomo Pharma (Suzhou) Co.,

   Bipolar Depression

   phase 3 · small molecule · completed

   1 trial →

10. Placebo

    Biogen

    Multiple Sclerosis, Remittent Progressive

    phase 3 · small molecule · completed

    1 trial →

11. Placebo

    Blackmores Limited

    Parkinsons Disease (PD)

    phase 3 · small molecule · active

    1 trial →

12. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 · small molecule · completed

    2 trials →

13. Placebo cannabis oil. Components: cannabis gr... for Refractory Epilepsy

    Disc Medicine

    Refractory Epilepsy

    phase 3 · small molecule · active

    1 trial →

14. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 · small molecule · active

    1 trial →

15. Placebo, XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 · small molecule · active

    1 trial →

16. Pramipexol Extended Release

    Boehringer Ingelheim

    Early Parkinson Disease (Early PD)

    phase 3 · small molecule · completed

    1 trial →

17. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 · small molecule · active

    7 trials →

18. RBP-7000

    Indivior Pty Ltd

    Schizophrenia

    phase 3 · small molecule · completed

    5 trials →

19. RGH-188-203

    Gedeon Richter Plc.

    Adolescent patient (13-17 years of age) with Schizophrenia

    phase 3 · small molecule · active

    1 trial →

20. RGH-MD-20

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 · small molecule · active

    1 trial →

21. RO7046015, Placebo Prasinezumab

    Hoffmann-La Roche

    Early-Stage Parkinson’s Disease (PD)

    phase 3 · small molecule · active

    1 trial →

22. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

23. Rivastigmine Transdermal System

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 3 · small molecule · completed

    1 trial →

24. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 · small molecule · completed

    1 trial →

25. SAVE PAIN 2025

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 · small molecule · active

    1 trial →

26. SPD489

    Takeda

    Schizophrenia

    phase 3 · small molecule · terminated

    1 trial →

27. SPD489 40mg

    Takeda

    Schizophrenia

    phase 3 · small molecule · terminated

    1 trial →

28. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 · small molecule · terminated

    1 trial →

29. SPD489-335

    Takeda

    Schizophrenia

    phase 3 · small molecule · terminated

    1 trial →

30. Seroquel Sustained Release (SR)

    AstraZeneca

    Schizophrenic Disorder

    phase 3 · small molecule · completed

    1 trial →

31. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

32. TG1101-RMS-PED304

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

33. TG1101-RMS401

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 · small molecule · active

    1 trial →

34. TV-44749

    Teva Pharma GmbH

    Schizophrenia

    phase 3 · small molecule · completed

    3 trials →

35. TV-46000

    Teva Pharma GmbH

    Schizophrenia

    phase 3 · small molecule · completed

    2 trials →

36. TV48125-CNS-30084

    Lacuna Pharma Pty Ltd

    Episodic and Chronic Migraine

    phase 3 · small molecule · active

    1 trial →

37. TVP-1012

    Takeda

    Parkinson's Disease

    phase 3 · small molecule · completed

    1 trial →

38. TVP-1012 1mg

    Takeda

    Parkinson's Disease

    phase 3 · small molecule · completed

    3 trials →

39. Teriflunomide

    Merck KGaA, Darmstadt, Germany

    Relapsing Multiple Sclerosis

    phase 3 · small molecule · terminated

    1 trial →

40. Tolebrutinib

    Sanofi Pasteur

    Non-relapsing Secondary Progressive Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

41. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 · small molecule · active

    3 trials →

42. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 · mab · active

    3 trials →

43. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

44. VP4896

    Voyager Therapeutics

    Alzheimer's Disease

    phase 3 · small molecule · completed

    1 trial →

45. WA40404

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 · small molecule · active

    1 trial →

46. WN42086

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

47. WN45443

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 · small molecule · active

    1 trial →

48. WN45447

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 · small molecule · active

    1 trial →

Frequently asked questions